Lack of drug interactions between mirtazapine and risperidone in psychiatric patients: A pilot study

European Neuropsychopharmacology

Volumn 10, Issue 1, 1999, Pages 51-57

  Loonen, A J M ^a,b   Doorschot, C H ^b   Oostelbos, M C J M ^b   Sitsen, J M A ^c  

^a Delta Psychiatrisch Ziekenhuis   (Netherlands)

^b Reinier van Arkel Groep   (Netherlands)

^c NV ORGANON   (Netherlands)

Author keywords

Antidepressant, MASEAS, SADJMoD; Antipsychotic; Drug drug interaction; Mirtazapine; Risperidone

Indexed keywords

MIRTAZAPINE; PALIPERIDONE; RISPERIDONE;

ADULT; AGED; ARTICLE; ATAXIA; CLINICAL ARTICLE; CLINICAL TRIAL; DEPRESSION; DRUG BLOOD LEVEL; DYSKINESIA; DYSTONIA; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSYCHOSIS; TREMOR;

ADULT; AGED; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIPSYCHOTIC AGENTS; DEPRESSION; DEPRESSIVE DISORDER; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; DYSTONIA; FEMALE; HUMANS; ISOXAZOLES; MALE; MIANSERIN; MIDDLE AGED; PILOT PROJECTS; PSYCHOTIC DISORDERS; PYRIMIDINES; RISPERIDONE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0032714390     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(99)00054-1     Document Type: Article

References (23)

1. Berendsen H.H.G., Broekkamp C.L.E., Pinder R.M. Mirtazapine enhances the effect of haloperidol on apomorphineinduced climbing behaviour in mice and attenuates haloperidolinduced catalepsy in rats. Psychopharmacology. 135:1998;284-289.
2. Brøsen K. Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry. Ther Drug Mon. 18:1996;393-396.
3. Davies A., Adena M.A., Keks N.A., Catts S.V., Lambert T., Schweitzer I. Risperidsone versus haloperidol: I. Meta-analysis of efficacy and safety. Clin. Ther. 20:1998;58-71.
4. Davis R., Wilde M.I. Mirtazapine. A review of its pharmacology and therapeutic potential in the management of major depression. CNS Drugs. 5:(suppl 5):1996;389-402.
5. 2-adrenoceptor antagonist mirtazapine (Org 3770) enhances noradrenergic and 5HT1 A-mediated serotonergic neurotransmission. CNS Drugs. 4:(suppl 1):1995;29-38.
6. 2-antagonist Org 3770 enhances serotonin transmission in vivo. Eur. J. Pharmacol. 253:1994;R5-R6.
7. Fang J., Bourin M., Baker G.B. Metabolism of risperidone to 9-hydroxy-risperidone by human cytochromes P450 2D6 and 3A4. Naun. Schmied. Arch. Pharmacol. 359:1999;147-151.
8. Gram L.F., Pedersen O.L., Kristensen C.B., Bjerre M., KraghSorensen P. Drug level monitoring in psychopharmacology: usefulness and clinical problems, with special reference to tricyclic antidepressants. Ther. Drug Mon. 4:1982;17-25.
9. Guy W. ECDEU assessment manual for psychopharmacology, revised. DHEW Pub. No. (ADM) 76-338. 1976;217-222 National Institute of Mental Health, Rockville, MD.
10. Huang M.L., Van Peer A., Woestenborghs R., De Coster R., Heykants J., Janssen A.I.J., Zylicz Z., Visscher H.W., Jonkman J.H.G. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin. Pharmacol. Ther. 54:1993;257-268.
11. Kasper S. Clinical efficacy of mirtazapine: a review of metaanalyses of pooled data. Int. Clin. Psychopharmacol. 10:(suppl 4):1995;25-37.
12. Kerwin R., Taylor D. New antipsychotics. A review of their current status and clinical potential. CNS Drugs. 6:1996;71-82.
13. 2 antagonists on haloperidol-induced dyskinesias in squirrel monkeys: no evidence for reciprocal 5-HT-dopamine interaction. Psychopharmacology. 97:1989;456-461.
14. Loga S., Curry S., Lader M. Interaction of chlorpromazine and nortriptyline in patients with schizophrenia. Clin. Pharmacokin. 6:1981;454-462.
15. Loonen A.J.M., Doorschot C.H. Klinisch veiligheidsonderzoek van geneesmiddelen: structuur van een documentatiesysteem. Ziekenhuisfarmacie. 10:1994;41-44.
16. Loonen A.J.M., Engberink M.H.A., Doornbos M., Doorschot C.H. Scale for the assessment of drug-induced movement disorders. Meeting of the Dutch Society for Clinical Pharmacology and Biopharmacy, Nijmegen, 8 October 1993 :1993.
17. Loonen A.J.M., Engberink M.H.A., Doornbos M., Doorschot C.H. Scale for the assessment of drug-induced movement disorders (SADIMoD)-Optimalization of video-registration procedure. XIXth CINP Congress, Washington DC, June 27-July 1, 1994 :1993.
18. Loonen A.J.M., Doorschot C.H., Jogems-Kosterman B.J.M., Van Hooff J.J.M., Hulstijn W., Zitman F.G. Nieuw instrumentarium voor het meten van bijwerkingen. Cobo Bull. 30:1997;31-40.
19. Montgomery S.A. Safety of mirtazapine: a review. Int. Clin. Psychopharmacol. 10:(suppl 4):1995;38-45.
20. Mulsant B.H., Foglia J.P., Sweet R.A., Rosen J., Lo K.H., Pollock B.G. The effects of perphenazine on the concentration of nortriptyline and its hydroxymetabolites in older patients. J. Clin. Psychopharmacol. 17:1997;318-321.
21. Paanakker J.E., Van Hal H.J.M. Capillary gas chromatographic assay for the routine monitoring of the antidepressant mepirzepine in human plasma. J. Chromatogr. Biomed. Appl. 417:1987;203-207.
22. Richelson E. Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. Mayo Clinic Proc. 72:1997;835-847.
23. 1A autoreceptors by the local application of 8-OH-DPAT reverses raclopride-induced catalepsy in the rat. Neuropharmacology. 34:1995;495-499.